The short answer
Med spas are acquired by five types of buyer: individual operators, independent sponsors and search funds, regional strategic groups, sponsor-backed platforms making tuck-in acquisitions, and institutional buyers acquiring platforms outright. Only a small minority of US med spas are private-equity consolidated, and that fragmentation — rather than any recent change in the sector — is why acquirers are active.
Quick answers
Seven narrow questions, one sentence each. These catch conversational queries that don’t warrant reading the article. Phrased deliberately differently from the FAQ at the bottom, and not included in the FAQPage schema — two Question entities sharing a name but not an answer is a quality problem.
Is the med spa market consolidating? Slowly — the large majority of US practices remain independently owned, which is early by the standards of most healthcare verticals.
What does a private equity buyer actually want from my practice? Earnings that continue without you, in a market where they already own or intend to own other locations.
Why would a platform pay more than an individual buyer? Because your earnings are worth more inside a larger business than they are on their own — the difference is explained below.
Does a higher multiple mean a better offer? Not reliably; a higher multiple with heavy deferred consideration can deliver less certain value than a lower all-cash offer.
Am I obliged to respond to an unsolicited approach? No, and a polite acknowledgement without figures commits you to nothing.
How do I check whether a buyer is who they say they are? Verify current ownership against a primary source — a sponsor’s own portfolio page, a filing, or named reporting — because industry lists frequently disagree.
Is staying independent a realistic option? Yes, and in a market this fragmented it remains a legitimate long-term strategy rather than a failure to act.
Key takeaways
- Fragmentation, not novelty, explains the acquisition interest — most US med spas are still independently owned.
- Private equity returns in this sector come principally from multiple expansion, not from operational improvement, and understanding that changes how you read an offer.
- Your practice is worth one number standing alone and a different number inside a platform; the gap is real, and access to any of it depends on more than one buyer competing.
- Rollover equity is a claim on that gap, which makes its governance and dilution terms more consequential than its headline percentage.
- Published ownership information about med spa platforms is frequently wrong — verify any buyer’s stated backing against a primary source before relying on it.
How consolidated is the med spa market?
Barely. Industry data places private-equity consolidation at a small share of US med spas, with the large majority still independently owned — against a sector counted in five figures of locations and measured in tens of billions of dollars of annual revenue.
American Med Spa Association industry data puts private-equity consolidation at roughly 3 to 4 percent of US med spas, with more than 90 percent independently owned. AmSpa’s 2024 State of the Industry Report counted approximately 10,488 US locations generating over $17 billion in 2024 revenue.
Hold those two facts next to each other, because the gap between them is the entire story.
A sector above $17 billion — growing, collected directly from patients rather than from insurers, with repeat demand built into the clinical reality of the treatments — and almost none of it owned by anyone institutional.
In most healthcare verticals that window closed years ago. Dermatology, dental, veterinary and ophthalmology have all consolidated well past this point.
Medical aesthetics is early. That is why capital is arriving, and it is why an owner today has more negotiating leverage than an owner in a mature vertical does. Buyers competing for scarce quality assets behave differently from buyers picking through what is left.
It is also why the emails will not stop.
Why does private equity buy med spas?
Private equity buys med spas because the sector is fragmented, revenue is collected directly from patients rather than from insurers, treatments repeat, and margins are strong. Combining many small practices into one platform then produces a larger business that sells for a higher multiple than the sum of its parts.
Five features make the sector attractive to institutional capital. Four of them are about the businesses. The fifth is where the returns actually come from.
Cash-pay revenue
No insurance billing, no payer contracts, no reimbursement risk, no denials. For a healthcare investor this removes the single largest source of uncertainty in the model, and it is the first thing that appears in any med spa investment thesis.
Repeat demand, built into the treatment
Neuromodulators wear off. Filler is maintained. Laser courses run in series. The clinical reality of the treatments produces a return-visit pattern without any marketing effort at all.
That is precisely the behaviour a subscription investor pays for, and it exists here without anyone having to engineer it.
Fragmentation
Thousands of independent operators means a long runway of acquisition targets. A roll-up needs raw material, and this sector has more of it than almost any comparable healthcare vertical.
Margin
Injectable gross margins are strong, and the operating model scales without the fixed-cost burden of a surgical facility or a hospital relationship.
Multiple expansion — the actual thesis
The one that drives the returns, and the one owners are least likely to have explained to them. It has its own section below.
Worth noticing what is not on that list: your brand, your reputation, and your relationship with your patients. Those affect the price at the margin. They are not the thesis, and an owner who believes otherwise tends to be surprised by the structure of the offer that eventually arrives.
What is the roll-up playbook?
The strategy is standardised across healthcare, and understanding the sequence tells you where your practice fits and what the buyer needs from it.
Phase 1 — Acquire a platform. A sponsor buys a larger, well-run group as the foundation. This business needs real management, real systems, and enough scale to absorb others.
Phase 2 — Add tuck-ins. Smaller practices are acquired and folded into the platform. This is where most readers of this page sit. Tuck-ins are bought for density — a practice that gives the platform a market it wants is worth more than an identical practice somewhere it does not.
Phase 3 — Professionalise. Central marketing, shared procurement, standard protocols, common technology, back-office consolidation. Costs come out; margin goes up.
Phase 4 — Exit. The platform is sold to a larger sponsor or a strategic acquirer, at a multiple no individual practice could achieve alone.
What the sequence tells you
The returns are produced in Phase 4. Phases 1 through 3 exist to make Phase 4 possible.
This is not a criticism of the model — it is simply what the model is, and it is disclosed in every fund document ever written. But it has a practical consequence for a seller.
When a buyer emphasises how much they value your local brand and your team, both things can be entirely true, and the plan still ends at Phase 4. If your continuing role, your brand, or your staff’s working conditions matter to you, they need to be negotiated as terms rather than trusted as intentions.
What is multiple arbitrage — and why does it matter to you?
Multiple arbitrage is the gap between what a buyer pays for a single practice and what that practice is worth once it sits inside a larger platform. It is the most useful concept in this entire subject, and almost no owner is told about it before signing.
Industry reporting places tuck-in acquisitions at roughly 5.5x to 8x adjusted EBITDA on the acquired basis, uplifting to 8x to 12x post-synergy inside the platform, with platform-scale businesses above roughly $10 million of adjusted EBITDA transacting in a 10x to 14x band.
The arithmetic
Work an example.
A practice with $1.2 million of adjusted EBITDA is acquired at 6x. That is $7.2 million.
Inside the platform, after integration, that same earnings stream carries the platform’s multiple. If the platform eventually trades at 11x, the acquirer has converted $7.2 million of cost into roughly $13 million of enterprise value — before a single operational improvement.
Illustrative. Multiples used for arithmetic only; not a market claim.
Where the gap comes from
It is not a trick, and it is worth saying so plainly.
The gap is genuinely created — by scale, by systems, by diversification across locations and service lines, and by the reduction in key-person risk that comes from owning forty practices rather than one. The platform supplies all of that. It is real value, and the platform is entitled to it.
Two things that follow for you
You are being priced on a spread. There is more room in an offer than the buyer’s first number implies. Whether you access any of it depends almost entirely on whether more than one buyer is competing for the practice — which is a process question, not a negotiating-skill question.
Rollover equity is a claim on the arbitrage. When a platform proposes that you retain a stake rather than take all cash, they are offering you a share of Phase 4. That can be the most valuable component of the deal, or it can be worth nothing, and which one it turns out to be is not knowable at signing.
Which makes the terms of that stake — governance, information rights, dilution, drag-along, valuation mechanics, what happens if your role ends — considerably more consequential than the percentage on the front page.
Who are the buyers, and what does each one want?
Five types acquire med spas. Locating yourself among them is the fastest way to understand which approaches deserve a substantive reply.
| Buyer type | Target size | Typical basis | What they are buying | You, afterwards |
|---|---|---|---|---|
| Individual operator | Single location, owner-operated | SDE, sometimes with seller financing | A business with an income and a patient base | Fully out after a short handover |
| Independent sponsor or search fund | Roughly $500K–$3M of earnings | Bank debt plus equity co-invest | A first platform, or a standalone operating asset | Out, or a short consulting period |
| Regional strategic group | Practices adjacent to their footprint | Adjusted EBITDA, cash-heavy | Geography, provider density, market share | Short transition, sometimes a role |
| Sponsor-backed platform, tuck-in | Roughly $1M–$5M adjusted EBITDA | Adjusted EBITDA, structured | Density in a market they have targeted | Defined role, integrated, often rollover |
| Institutional platform buyer | $10M+ adjusted EBITDA | Adjusted EBITDA | A platform to own, scale, and resell | Significant continuing involvement |
Two practical notes
Independent sponsors expanded into this sector through the current cycle, once the tuck-in thesis had been validated by named sponsors. That means a greater share of the approaches an owner receives now come from buyers who do not yet have committed capital behind them.
Asking about it early is fair, unembarrassing, and genuinely informative: is your funding committed, or are you raising it if we agree terms?
The tier that contacts you is not necessarily the tier you should sell to. Whichever buyer found you first is a function of their outreach process, not of your practice’s best fit. That depends on whether you want out or want a partner — which is the final section of this page.
What do buyers score you on?
Buyers assess transferability first — whether the earnings survive your departure — then recurring revenue, provider retention, service-mix balance, patient retention, compliance and structure, and whether the financial records withstand an independent review.
Use the list below as a self-assessment before someone else conducts it for you.
| What they assess | What good looks like | What it costs you if weak |
|---|---|---|
| Transferability | You deliver a minority of revenue; patients follow the brand | The largest single discount in the sector |
| Recurring revenue | Membership and prepaid a meaningful share of the top line | Forgoes the clearest multiple premium available |
| Provider retention | Tenured injectors, under agreement, secured through transition | Heavy earnout, or no deal |
| Service mix | Balanced across injectables, devices and other lines | Concentration risk discount |
| Patient retention | Strong repeat rate, genuinely active patient file | Revenue read as promotional rather than durable |
| Compliance and structure | Current agreements, documented supervision, defensible structure | Stalled diligence; occasionally a dead deal |
| Financial quality | Books survive a quality of earnings review unrestated | Price reduction after the letter of intent |
The pattern running through every row: buyers pay for evidence, not for assertion. A practice that can demonstrate its retention with data is worth more than an identical practice whose owner describes it accurately but cannot document it.
Six of the seven are improvable within twenty-four months. Only scale takes longer.
The Med Spa Platform Directory
Last verified: [DATE] · Reviewed quarterly · [n] platforms published
Methodology, and why it is the point
Every entry is sourced to a primary announcement — a sponsor or company press release, a regulatory filing, or named reporting from an established outlet. Where ownership could not be confirmed to a primary source, the platform is listed without a sponsor attribution rather than with an unverified one. Sponsor relationships change, so every row carries the date it was last checked.
We publish this because the alternative sources contradict one another. While compiling it, we found four different financial sponsors attributed to the same platform across four industry pages.
That matters if you are evaluating an approach. “We’re backed by [well-known firm]” is a meaningful claim — it affects how much capital sits behind an offer, how patient that capital is, and what the eventual exit looks like. It is also easy to state and rarely checked.
If you are looking at a named buyer right now, verify current ownership before relying on any list. Including this one.
| Platform | Sponsor(s) | Scale | Acquisition profile | Source | Last verified |
|---|---|---|---|---|---|
| LaserAway | Founders, Ares Management, Seidler Equity Partners | 219 clinics as of May 2026; approximately $150M annual EBITDA reported | National laser and aesthetics platform; engaged Harris Williams in June 2026 for a sale process reported to target above $2 billion | Reuters, 4 June 2026; Business Wire, 21 October 2021 | [DATE] |
Strategic acquirers, which behave differently
Manufacturers such as AbbVie/Allergan Aesthetics, Galderma and Merz are not service-channel acquirers at scale, and they do not belong in the directory above.
They matter for a different reason. Loyalty programme status, tier standing, and authorised-distributor purchasing records appear as gating items in buyer diligence. Worth understanding before your procurement records are examined rather than during.
What changed in 2026?
Three shifts an owner should factor into their thinking.
The cost of capital came down, but did not reset
The federal funds target range sat at 3.50 to 3.75 percent following the June 2026 FOMC decision.
Multiples across the sector compressed during the 2023–24 rate rise and have since stabilised rather than returned to their peak. What moved pricing was the cost of money, not consumer demand — a distinction worth holding on to when reading commentary that attributes multiple compression to the sector losing its appeal.
Compliance became a deal issue rather than a footnote
California’s SB 351 took effect on 1 January 2026, restricting how private equity groups, hedge funds and management services organisations can influence licensed practices, with AB 1415 extending transaction reporting obligations. Enforcement followed.
For an owner, this means structural diligence goes deeper and management services agreements drafted before 2025 may need amendment.
Scale is being tested at the top of the market
Reuters reported in June 2026 that LaserAway — backed by its founders, Ares Management and Seidler Equity Partners — was running a sale process reported to target a valuation above $2 billion against roughly $150 million of annual EBITDA.
Where that process lands is the clearest live read on what institutional capital will pay for a national platform, and it will influence platform pricing beneath it — which in turn influences what tuck-in buyers can afford to pay you.
Sell, partner, or stay independent?
Three genuine options. Most content in this sector presents one.
| Sell outright | Partner with a platform | Stay independent | |
|---|---|---|---|
| Cash now | Highest | Partial | None |
| Upside later | None | Rollover equity, if the platform exits well | All of it, if you build it |
| Control | Ends | Shared — board, platform standards | Retained |
| Risk | Lowest | Concentrated in someone else’s execution | Entirely yours |
| Suits | Owners ready to be finished | Owners with growth ambition and no capital | Owners who like the business and have time |
Two things worth saying plainly.
Staying independent is a strategy, not a failure to act. A market this fragmented will not be fully consolidated soon, and a well-run independent practice with a strong local brand can operate profitably for a very long time. If you enjoy the work, no is a complete and legitimate answer to every email you receive.
The preparation is not wasted either way. Cleaner financials, less owner dependency, more recurring revenue and better documentation make a practice better to own, not merely easier to sell. That is the rare piece of advice in this field with no downside attached, and it is the reason this page ends without recommending a course of action.
Frequently asked questions
Why does private equity buy med spas? Because the sector is fragmented, revenue is collected directly from patients rather than from insurers, treatments repeat, and margins are strong. Combining many small practices into a platform produces a business that sells for a higher multiple than the sum of its parts.
What percentage of med spas are private-equity owned? A small minority — industry data places consolidation at roughly 3 to 4 percent of US med spas, with more than 90 percent independently owned. That fragmentation is the reason acquirers are competing rather than picking through what is left.
What is multiple arbitrage? The gap between what a buyer pays for a single practice and what it is worth inside a larger platform. The uplift is genuinely created by scale, systems and reduced key-person risk — but it means there is more room in an offer than the first number implies.
What does a private equity buyer look for in a med spa? Transferability above everything — whether earnings survive your departure. Then recurring revenue, provider retention, service-mix balance, patient retention, clean structure, and financial records that withstand an independent review.
How do I check who really owns a platform that has approached me? Verify against a primary source: the sponsor’s own portfolio page, a regulatory filing, or named reporting from an established outlet. Industry directories frequently disagree with one another, and several published attributions are demonstrably wrong.
Should I reply to an unsolicited approach from a platform? Replying costs nothing. Discussing numbers before you have an independent view of value costs a great deal, because an unsolicited approach means a buyer decided your practice was worth acquiring before you decided to sell.
Is it better to sell to a platform or to an individual buyer? Neither is better in the abstract. Platforms typically pay more and structure more, individual buyers typically pay less and pay it in cash, and the right answer depends on whether you want out or want a partner.
